Sökning: "Primary tumour cells"
Visar resultat 1 - 5 av 116 avhandlingar innehållade orden Primary tumour cells.
1. Unconventional T cells in colon adenocarcinomas
Sammanfattning : Many factors influence the initiation and growth of tumours. The infiltration and activity of immune cells in the tumour microenvironment are widely recognised as key factors affecting the clinical outcome of cancer. LÄS MER
2. MESENCHYMAL STEM- AND STROMAL CELLS IN BONE MARROW AND OSTEOSARCOMA
Sammanfattning : Primary mesenchymal stem cells (MSC) play a central role in bone marrow (BM) and during haematopoiesis. Yet, the exact phenotype and spatial distribution of primary MSC in the human BM are unknown. Their cultured progeny are promising candidates for clinical applications. LÄS MER
3. Prognostic role of the tumour microenvironment in esophago-gastric, pancreatic and periampullary adenocarcinoma: B cells and beyond
Sammanfattning : Cancer development depends on cells aquiring a skillset of limitless growth and finally invasive properties to allow for metastasis, as summarised by the six hallmarks of cancer. Recently four more hallmarks have been added: genomic instability, deregulating cellular metabolism, tumour-promoting inflammation and avoiding immune destruction. LÄS MER
4. Stromal collagens in colorectal cancer and in colorectal liver metastases : tumour biological implications and a source for novel tumour markers
Sammanfattning : Background: Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality. About 50 % of patients with CRC will develop subsequent liver metastases (CLM). The survival for untreated CLM is only a few months and liver resection provides the only chance for a lasting cure. LÄS MER
5. Specific anti-tumour effects of 6-diazo-5-oxo-L-norleucine (DON) on carcinoid tumour cells
Sammanfattning : Glutamine is essential for cell growth. 6-diazo-5-oxo-L-norleucine (DON) is a rather old anti-tumour drug developed as a glutamine antagonist. Previous clinical trials with DON, not including carcinoid tumours, did not prove convincing. Hence the drug was not further used. LÄS MER